Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a Phase 3 study titled A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa. The study aims to assess the disease activity and safety of Lutikizumab, an investigational drug, in treating moderate to severe Hidradenitis Suppurativa (HS), a chronic inflammatory skin condition.
The intervention being tested is Lutikizumab, administered via subcutaneous injection. The study compares Lutikizumab to a placebo in reducing the symptoms of HS.
This is a randomized, triple-masked study with a parallel intervention model. Its primary purpose is treatment, and it involves multiple phases, including an open-label extension for long-term assessment.
The study began on June 27, 2024, with a primary completion date yet to be announced. The latest update was submitted on July 29, 2025. These dates are crucial for tracking the study’s progress and anticipated results.
The study’s outcome could significantly impact AbbVie’s stock performance, as positive results may enhance investor confidence and market position in the competitive pharmaceutical industry. The ongoing recruitment and updates suggest active progress in the study.
The study is ongoing, with further details available on the ClinicalTrials portal.